News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tamir Biotechnology, Inc. (Formerly Known as Alfacell Corporation) (ACEL) Announces Selection of CRO


7/6/2010 1:10:38 PM

SOMERSET, N.J., July 6, 2010 (GLOBE NEWSWIRE) -- Tamir Biotechnology, Inc. (formerly known as Alfacell Corporation) (OTCBB:ACEL) today announced that it has selected Pharmatech Oncology, Inc. as the Clinical Research Organization (CRO) to run its upcoming Phase II trial of RANPIRNASE (ONCONASE®) in combination with platinum doublet chemotherapy for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES